| 12421197 |
Aminopyrazine derivatives as PI3K-γ inhibitors |
Brent Douty, Yanran Ai, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh +6 more |
2025-09-23 |
|
| 12325706 |
Polymorphic form of sepiapterin |
Hiroshi Yoshino, Taichi Komoda, Yuichi Shiro, Shunichi Murata, Takayoshi MATSUMOTO +1 more |
2025-06-10 |
|
| 12269829 |
Polymorphs of sepiapterin and salts thereof |
— |
2025-04-08 |
|
| 12213982 |
Pharmaceutical compositions comprising sepiapterin and uses thereof |
— |
2025-02-04 |
|
| 12173006 |
Crystalline forms of a phosphoinositide 3-kinase (PI3K) inhibitor |
Brent Douty, David M. Burns, Andrew P. Combs, Zhongjiang Jia, Eddy W. Yue |
2024-12-24 |
$95,588,000 |
| 12030885 |
Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors |
Andrew W. Buesking, Richard B. Sparks, Andrew P. Combs, Brent Douty, Nikoo Falahatpisheh +5 more |
2024-07-09 |
$15,981,000 |
| 11926630 |
Tertiary alcohols as PI3K-γ inhibitors |
Brent Douty, Andrew W. Buesking, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh +7 more |
2024-03-12 |
$38,520,000 |
| 11780840 |
Tricyclic urea compounds as JAK2 V617F inhibitors |
Yanran Ai, Onur Atasoylu, Yu Sheng Bai, Joseph Barbosa, David M. Burns +11 more |
2023-10-10 |
$36,712,000 |
| 11773097 |
Polymorphs of sepiapterin and salts thereof |
— |
2023-10-03 |
$22,734,000 |
| 11752154 |
Pharmaceutical compositions comprising sepiapterin and uses thereof |
— |
2023-09-12 |
$15,490,000 |
| 11746119 |
Cardiopathy-reducing phosphodiester lipids |
James D. McChesney, Annie Bouchard, Saravanan Kappusamy, John Kallikat Augustine |
2023-09-05 |
|
| 11661422 |
Tricyclic urea compounds as JAK2 V617F inhibitors |
Kai Liu, Brent Douty, Liangxing Wu, Wenqing Yao, Eddy W. Yue |
2023-05-30 |
$79,121,000 |
| 11643424 |
Cardiopathy-reducing phosphodiester lipids |
James D. McChesney, Annie Bouchard, Saravanan Kappusamy, John Kallikat Augustine |
2023-05-09 |
|
| 11325908 |
CaMKII inhibitors and uses thereof |
Howard Schulman, Bheema R. Paraselli, Nangunoori Sampath Kumar, Brahmaiah Dabbugoddu, Chundru Balasubramanyam |
2022-05-10 |
$37,579,000 |
| 11225486 |
Tertiary alcohols as PI3K-γ inhibitors |
Brent Douty, Andrew W. Buesking, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh +7 more |
2022-01-18 |
$120,701,000 |
| 11186580 |
Crystalline forms of a phosphoinositide 3-kinase (PI3K) inhibitor |
Brent Douty, David M. Burns, Andrew P. Combs, Zhongjiang Jia, Eddy W. Yue |
2021-11-30 |
$101,590,000 |
| 11130760 |
Polymorphic form of sepiapterin |
Hiroshi Yoshino, Taichi Komoda, Yuichi Shiro, Shunichi Murata, Takayoshi MATSUMOTO +1 more |
2021-09-28 |
$25,226,000 |
| 11072614 |
Polymorphs of sepiapterin and salts thereof |
— |
2021-07-27 |
$23,974,000 |
| 11046658 |
Aminopyrazine derivatives as PI3K-γ inhibitors |
Brent Douty, Yanran Ai, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh +6 more |
2021-06-29 |
$68,992,000 |
| 10975111 |
Cardiopathy-reducing phosphodiester lipids |
James D. McChesney, Annie Bouchard, Saravanan Kappusamy, John Kallikat Augustine |
2021-04-13 |
|
| 10975088 |
Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors |
Andrew W. Buesking, Richard B. Sparks, Andrew P. Combs, Brent Douty, Nikoo Falahatpisheh +5 more |
2021-04-13 |
$77,418,000 |
| 10759792 |
CaMKII inhibitors and uses thereof |
Howard Schulman, Bheema R. Paraselli, Nangunoori Sampath Kumar, Brahmaiah Dabbugoddu, Chundru Balasubramanyam |
2020-09-01 |
|
| 10738057 |
Tertiary alcohols as PI3K-γ inhibitors |
Brent Douty, Andrew W. Buesking, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh +7 more |
2020-08-11 |
$88,019,000 |
| 10479795 |
Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines and substituted imidazo[1,2-b]pyridazines as PI3K-gamma inhibitors |
Andrew W. Buesking, Richard B. Sparks, Andrew P. Combs, Brent Douty, Nikoo Falahatpisheh +5 more |
2019-11-19 |
$68,835,000 |
| 10081633 |
Adenylyl cyclase inhibitors, pharmaceutical compositions and method of use thereof |
Patricio Abarzua |
2018-09-25 |
|
